SIREN : 801321969
PONTIPHARMA is a French company founded 12 years ago, specialized in the sector Réparation de machines et équipements mécaniques. Based in PORT-DE-BOUC (13110), this company of category ETI shows in 2024 a revenue of 4.4 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 368 816 € | 4 405 762 € | 4 488 518 € | 4 682 908 € | 4 612 562 € | 4 153 746 € | 4 487 934 € | 4 196 501 € | 4 364 680 € |
| Net income | 75 938 € | 31 380 € | -131 145 € | 4 730 € | 8 377 € | 5 828 € | 118 255 € | 102 063 € | 159 953 € |
| EBITDA | 69 278 € | 31 605 € | -131 532 € | 6 317 € | 11 628 € | 6 691 € | 110 862 € | 84 145 € | 159 603 € |
| Net margin | 1.7% | 0.7% | -2.9% | 0.1% | 0.2% | 0.1% | 2.6% | 2.4% | 3.7% |
In 2024, PONTIPHARMA achieves revenue of 4.4 M€. Revenue is growing positively over 9 years (CAGR: +0.0%). Slight decline of -1% vs 2023. After deducting consumption (193 k€), gross margin stands at 4.2 M€, i.e. a rate of 96%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 69 k€, representing 1.6% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 76 k€, i.e. 1.7% of revenue. This profit can be retained or distributed to shareholders.
4 368 816 €
4 175 353 €
69 278 €
69 277 €
75 938 €
1.6%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 1%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 1.7% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
0.0%
1.189%
1.738%
0.0
In 2024, the debt ratio of PONTIPHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of PONTIPHARMA (1.2%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of PONTIPHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 115.14. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.2x. Danger: operating income does not cover interest charges, unsustainable situation.
115.139
0.202
In 2024, the liquidity ratio of PONTIPHARMA (115.14) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of PONTIPHARMA (0.2x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 88 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 124 days. Excellent situation: suppliers finance 36 days of the operating cycle (retail model). Overall, WCR represents 143 days of revenue, i.e. 1.7 M€ to permanently finance. Over 2016-2024, WCR increased by +135%, requiring additional financing.
1 733 765 €
88 j
124 j
0 j
143 j
Based on 104 transactions of similar company sales (all years), the value of PONTIPHARMA is estimated at 407 656 € (range 225 439€ - 1 081 828€). With an EBITDA of 69 278€, the sector multiple of 1.0x is applied. The price/revenue ratio is 0.27x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 104 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare PONTIPHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Réparation de machines et équipements mécaniques
The revenue of PONTIPHARMA in 2024 is 4.4 M€.
Yes, PONTIPHARMA generated a net profit of 76 k€ in 2024.
The headquarters of PONTIPHARMA is located in PORT-DE-BOUC (13110), in the department Bouches-du-Rhone.
The tax return of PONTIPHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
PONTIPHARMA operates in the sector Réparation de machines et équipements mécaniques (NAF code 33.12Z). See the 'Sector positioning' section above to compare the company with its competitors.